Legislation roundup: Foreign Pharma Investors, GBA Data Transfer, and Non-Performing Assets

December 02, 2024 | BY

Susan Mok

Foreign marketing authorization holders are required to designate a domestic responsible person in China. Personal information handlers of the Greater Bay Area are required to make publicly available its rules for processing personal information. NFRA specifies the non-performing assets that a financial asset management company may acquire.

Healthcare

National Medical Products Administration, Tentative Provisions for the Administration of the Designation of a Domestic Responsible Person by Foreign Marketing Authorization Holders
国家药品监督管理局境外药品上市许可持有人指定境内责任人管理暂行规定

With respect to any one pharmaceutical product marketed in mainland China, the foreign marketing authorization holder shall designate a sole domestic responsible person therefor to perform the obligations of the marketing authorization holder. One domestic responsible person may accept designations by different foreign marketing authorization holders and for different imported pharmaceutical products.
The name, address and contact information of the domestic responsible person shall be provided in the directions for use of the pharmaceutical.

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]